logo

DRAGARWQ vs VAISHALI: Stock Comparison

DR. AGARWAL'S EYE HOSP L vs VAISHALI PHARMAUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

DR. AGARWAL'S EYE HOSP L is the larger company by market capitalisation. DR. AGARWAL'S EYE HOSP L shows a higher ROE, a higher dividend yield and lower leverage, while VAISHALI PHARMA shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

DRAGARWQ leads 10; VAISHALI leads 1 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

DRAGARWQVAISHALI

Valuation lens

What price are you paying?

Market CapContext only
₹2,455 Cr
₹98 Cr
P/E RatioSame reading
32.2x
—
P/B RatioSame reading
7.09x
—
EPSDRAGARWQ has the higher reading
₹48.38 ✓
₹0.12
Book ValueContext only
₹716.56
₹5.3
Dividend YieldDRAGARWQ has the higher reading
0.14% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
DRAGARWQ is the larger company
₹2,455 Cr vs ₹98 Cr
EPS
DRAGARWQ has higher earnings per share
₹48.38 vs ₹0.12
Dividend Yield
DRAGARWQ has a higher dividend yield
0.14% vs 0%
Revenue Growth (TTM YoY)
VAISHALI has faster revenue growth
18.35% vs 0%
EPS Growth (TTM YoY)
DRAGARWQ has faster EPS growth
0% vs -76.71%
Qtr Sales Growth
DRAGARWQ has stronger quarterly sales growth
19.13% vs 0%
Qtr Profit Growth
DRAGARWQ has stronger quarterly profit growth
43.97% vs 0%
ROE
DRAGARWQ has a higher ROE
20.24% vs 5.84%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRAGARWQVAISHALI
Sector—Healthcare
Industry—Pharmaceuticals

Price

MetricDRAGARWQVAISHALI
Live Price₹5,077.5₹7.54
Day Change0.01%-3.46%
Volume1,32871,977
52-Week High₹6,059.7₹11.15
52-Week Low₹4,600₹4.75
Distance from 52W High-16.21%-32.38%

Valuation

MetricDRAGARWQVAISHALI
Market Cap₹2,455 Cr₹98 Cr
P/E Ratio32.2x—
P/B Ratio7.09x—
EPS₹48.38₹0.12
Book Value₹716.56₹5.3
Dividend Yield0.14%0%

Growth

MetricDRAGARWQVAISHALI
Revenue Growth (TTM YoY)0%18.35%
EPS Growth (TTM YoY)0%-76.71%
Qtr Sales Growth19.13%0%
Qtr Profit Growth43.97%0%

Profitability & Leverage

MetricDRAGARWQVAISHALI
ROE20.24%5.84%
ROCE18.74%6.37%
Net Margin14.89%3.83%
Operating Margin22.4%6.76%
Debt to Equity0.24x0.27x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDRAGARWQVAISHALI
Promoter Holding72.67%31.61%
FII Holding2.24%▲ 0.04 pp0%
DII Holding2.05%▼ 0.07 pp0%
Public Holding23.04%▲ 0.04 pp68.39%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. AGARWAL'S EYE HOSP L and VAISHALI PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.